nyse:nvro
|
https://www.indeed.com/cmp/nevro-corporation
|
Aug 29th, 2022 12:00AM
|
Open
|
Nevro
|
|
|
Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
|
RRv1_25M_100M
|
Redwood City
|
|
|
|
3.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.00
|
21.00
|
3.30
|
3.50
|
2.70
|
2.90
|
3.10
|
6.00
|
About two weeks
|
9.00
|
MEDIUM
|
6.00
|
AVERAGE
|
|
|
|
Aug 29th, 2022 01:56PM
|
Aug 29th, 2022 01:56PM
|
Nevro
|
Health Care
|
Health Care Equipment & Services
|
nyse:nvro
|
https://www.indeed.com/cmp/nevro-corporation
|
Aug 28th, 2022 12:00AM
|
Open
|
Nevro
|
|
|
Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
|
RRv1_25M_100M
|
Redwood City
|
|
|
|
3.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.00
|
21.00
|
3.30
|
3.50
|
2.70
|
2.90
|
3.10
|
6.00
|
About two weeks
|
9.00
|
MEDIUM
|
6.00
|
AVERAGE
|
|
|
|
Aug 28th, 2022 07:32AM
|
Aug 28th, 2022 07:32AM
|
Nevro
|
Health Care
|
Health Care Equipment & Services
|
nyse:nvro
|
https://www.indeed.com/cmp/nevro-corporation
|
Aug 27th, 2022 12:00AM
|
Open
|
Nevro
|
|
|
Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
|
RRv1_25M_100M
|
Redwood City
|
|
|
|
3.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.00
|
21.00
|
3.30
|
3.50
|
2.70
|
2.90
|
3.10
|
6.00
|
About two weeks
|
9.00
|
MEDIUM
|
6.00
|
AVERAGE
|
|
|
|
Aug 27th, 2022 06:21AM
|
Aug 27th, 2022 06:21AM
|
Nevro
|
Health Care
|
Health Care Equipment & Services
|
nyse:nvro
|
https://www.indeed.com/cmp/nevro-corporation
|
Aug 25th, 2022 12:00AM
|
Open
|
Nevro
|
|
|
Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
|
RRv1_25M_100M
|
Redwood City
|
|
|
|
3.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
13.00
|
3.10
|
3.70
|
2.30
|
2.60
|
3.00
|
6.00
|
About two weeks
|
9.00
|
MEDIUM
|
6.00
|
AVERAGE
|
|
|
|
Aug 25th, 2022 10:54AM
|
Aug 25th, 2022 10:54AM
|
Nevro
|
Health Care
|
Health Care Equipment & Services
|
nyse:nvro
|
https://www.indeed.com/cmp/nevro-corporation
|
Aug 23rd, 2022 12:00AM
|
Open
|
Nevro Corporation
|
|
|
Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
|
RRv1_25M_100M
|
Redwood City
|
|
|
|
3.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
13.00
|
3.10
|
3.70
|
2.30
|
2.60
|
3.00
|
6.00
|
About two weeks
|
9.00
|
MEDIUM
|
6.00
|
AVERAGE
|
|
|
|
Aug 23rd, 2022 12:46PM
|
Aug 23rd, 2022 12:46PM
|
Nevro
|
Health Care
|
Health Care Equipment & Services
|
nyse:nvro
|
https://www.indeed.com/cmp/nevro-corporation
|
Aug 21st, 2022 12:00AM
|
Open
|
Nevro Corporation
|
|
|
Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
|
RRv1_25M_100M
|
Redwood City
|
|
|
|
3.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
13.00
|
3.10
|
3.70
|
2.30
|
2.60
|
3.00
|
6.00
|
About two weeks
|
9.00
|
MEDIUM
|
6.00
|
AVERAGE
|
|
|
|
Aug 21st, 2022 02:32PM
|
Aug 21st, 2022 02:32PM
|
Nevro
|
Health Care
|
Health Care Equipment & Services
|
nyse:nvro
|
https://www.indeed.com/cmp/nevro-corporation
|
Aug 20th, 2022 12:00AM
|
Open
|
Nevro Corporation
|
|
|
Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
|
RRv1_25M_100M
|
Redwood City
|
|
|
|
3.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
13.00
|
3.10
|
3.70
|
2.30
|
2.60
|
3.00
|
6.00
|
About two weeks
|
9.00
|
MEDIUM
|
6.00
|
AVERAGE
|
|
|
|
Aug 20th, 2022 04:12PM
|
Aug 20th, 2022 04:12PM
|
Nevro
|
Health Care
|
Health Care Equipment & Services
|
nyse:nvro
|
https://www.indeed.com/cmp/nevro-corporation
|
Aug 19th, 2022 12:00AM
|
Open
|
Nevro Corporation
|
|
|
Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
|
RRv1_25M_100M
|
Redwood City
|
|
|
|
3.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
13.00
|
3.10
|
3.70
|
2.30
|
2.60
|
3.00
|
6.00
|
About two weeks
|
9.00
|
MEDIUM
|
6.00
|
AVERAGE
|
|
|
|
Aug 19th, 2022 02:31PM
|
Aug 19th, 2022 02:31PM
|
Nevro
|
Health Care
|
Health Care Equipment & Services
|
nyse:nvro
|
https://www.indeed.com/cmp/nevro-corporation
|
Aug 18th, 2022 12:00AM
|
Open
|
Nevro Corporation
|
|
|
Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
|
RRv1_25M_100M
|
Redwood City
|
|
|
|
3.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
13.00
|
3.10
|
3.70
|
2.30
|
2.60
|
3.00
|
6.00
|
About two weeks
|
9.00
|
MEDIUM
|
6.00
|
AVERAGE
|
|
|
|
Aug 18th, 2022 07:09AM
|
Aug 18th, 2022 07:09AM
|
Nevro
|
Health Care
|
Health Care Equipment & Services
|
nyse:nvro
|
https://www.indeed.com/cmp/nevro-corporation
|
Aug 17th, 2022 12:00AM
|
Open
|
Nevro Corporation
|
|
|
Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
|
RRv1_25M_100M
|
Redwood City
|
|
|
|
3.10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.00
|
12.00
|
3.00
|
3.60
|
2.20
|
2.50
|
2.90
|
6.00
|
About two weeks
|
9.00
|
MEDIUM
|
6.00
|
AVERAGE
|
|
|
|
Aug 17th, 2022 11:53AM
|
Aug 17th, 2022 11:53AM
|
Nevro
|
Health Care
|
Health Care Equipment & Services
|